China marked World COPD Day on Wednesday with a set of figures that describe both the scale of chronic obstructive pulmonary disease and the reason it stays hidden: roughly 13.6 percent of adults aged 40 and over have it, an estimated 100 million people, but only a small fraction have ever been confirmed by spirometry.
COPD is now the country’s third leading cause of death. It develops slowly, its early symptoms are dismissed as smoker’s cough or age, and diagnosis requires a lung function test rather than a blood sample, which is why health authorities describe it as high prevalence, high mortality, high cost and low awareness.
The response has been a screening programme rather than a treatment campaign. A national project launched in 2021 for early detection and intervention among high-risk groups has so far run initial questionnaires on 3.47 million people, identified 791,000 as high risk, performed 493,000 spirometry tests and followed up 428,000.
Its two-step design, a symptom questionnaire followed by a lung function test, has been cited in The Lancet, and the reported high-risk detection rate of about 22 percent suggests the questionnaire is doing real filtering work rather than passing everyone through.
The programme’s second half is the harder one. Screening only helps if a positive result leads to inhalers and follow-up at a clinic the patient can reach, so the model relies on a four-tier network running from national centres down to township hospitals, with training for primary care doctors who have rarely had spirometry equipment.
Two policy changes this autumn support that. The 2026 national essential medicines list added the dual bronchodilators and triple combination therapies used for stable COPD, which addresses the complaint that rural patients were diagnosed but had nothing to take. A four-ministry document issued on 17 November sets out the next stage of chronic disease management.
For readers outside China the interest is structural. Ageing populations across Asia are heading for similar prevalence figures, and the choice between screening everyone and treating only those who show up symptomatic determines whether a health system pays for inhalers or for intensive care.

Dgcity